August 26, 2024 – Goldea Capital

Telix Announces Reorganisation to Deliver on Strategic Priorities

Written by Customer Service on August 26, 2024. Posted in Public Companies.

MELBOURNE, Australia, Aug. 27, 2024 (GLOBE NEWSWIRE) — Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces new leadership appointments as part of an internal reorganisation to align its operations across four business units, reflecting its focus as a therapeutics-led radiopharmaceutical company committed to precision oncology. The updated business model comprises: Therapeutics, Precision Medicine (Diagnostics), Lightpoint (Medtech) and Telix Manufacturing Solutions (TMS). As part of this initiative, the Company announces three leadership changes: Richard Valeix, Chief Executive Officer, Telix Therapeutics (formerly Group Chief Commercial Officer)1, leading the Company’s therapeutic pipeline commercialisation and business development; Kevin Richardson, Chief Executive Officer, Telix Precision Medicine...

Unifiedpost Group announces the sale of the Wholesale Identity Access business in the Netherlands – an opportunity for value crystallisation alongside an enhanced focus on core digital services

Written by Customer Service on August 26, 2024. Posted in Public Companies.

INSIDE INFORMATION La Hulpe, Belgium – August 26, 2024, Midnight– [INSIDE INFORMATION] Unifiedpost Group (Euronext Brussels: UPG) (Unifiedpost), a leading provider of integrated business communication solutions, announces the signing of a binding term sheet (Term Sheet) with Your.World B.V. (Your.World) for the sale of its Wholesale Identity Access business in the Netherlands (the Transaction). The Term Sheet outlines the sale of all shares in Unifiedpost B.V., following the carve-out of its non-Wholesale Identity Access business, for a base purchase price based on an enterprise value of € 133,0 million on a cash and debt-free basis, which includes an earn-out payment of up to € 7,7 million upon achieving certain financial milestones. The Transaction is part of a wider, new strategic partnership which is to be entered into between Unifiedpost...

Smart for Life Provides Update on Prospective Acquisitions

Written by Customer Service on August 26, 2024. Posted in Mergers And Acquisitions.

Multiple Acquisitions in Pipeline; Ranging from Definitive Agreement to Exploratory Discussions as Phase 2 of the Company’s Post-Restructuring Initiatives; Company Provides Update on Timing for Form 10-Q MIAMI, Aug. 26, 2024 (GLOBE NEWSWIRE) — Smart for Life, Inc. (Nasdaq: SMFL) (“Smart for Life” or the “Company”), a distinguished leader in the Health & Wellness sector specializing in the marketing and manufacturing of nutritional supplements and foods, today provided an update on the potential expansion of the Company’s acquisition pipeline and an update on its M&A activities. Currently, the Company is negotiating four profitable Health & Wellness acquisitions and exploring additional prospects as part of its post-restructuring strategy. These targets include Purely Optimal Nutrition, a liquid manufacturer, an established...

Clear Blue Technologies Announces Q2 2024 Financial Results

Written by Customer Service on August 26, 2024. Posted in Earnings Releases And Operating Results.

Trailing Four-Quarter Revenue Of $6.2M (+278% Y/Y Growth), Recurring Revenue Of ~$800K (+21% Y/Y Growth) and 43% Gross margin TORONTO, Aug. 26, 2024 (GLOBE NEWSWIRE) — Clear Blue Technologies International Inc. (TSXV: CBLU) (FRANKFURT: OYA), the Smart Off-Grid™ Company, announces its financial results for the second quarter of 2024 (“Q2 2024”) ending June 30, 2024. A complete set of Financial Statements and Management’s Discussion & Analysis (“MD&A”) has been filed at www.sedarplus.ca. All dollar amounts are denominated in Canadian dollars. On a Trailing Four Quarter (“TFQ”) basis: Revenue was $6,212,370, a 278% increase from $1,644,227 in the corresponding previous period, due to strong revenue growth across all four of Clear Blue’s product lines; Recurring revenue was $779,149 a 21% increase from $646,416 in...

Termination of ANH Contracts

Written by Customer Service on August 26, 2024. Posted in Public Companies.

Oslo, 26 August 2024 Interoil Exploration and Production ASA (the “Company“) announces that its Colombian subsidiary, Interoil Colombia Exploration and Production (“ICEP”), has reached an agreement with the Colombian National Hydrocarbons Agency –Agencia Nacional de Hidrocarburos– (the “ANH”) for a partial termination of the Exploration and Production contract between ICEP and the ANH over the LLA-47 block (the “LLA-47 Contract”). This contract termination is predicated upon the difficulties related to community’s unflinching opposition to exploration activities that have prevented normal development of activities and satisfaction of exploratory commitments for an extensive period of time, which motivated several time extensions and suspensions granted by the ANH to contract term. Under such partial termination,...

Report on Financial Results for the Three and Six Months Ended June 30, 2024

Written by Customer Service on August 26, 2024. Posted in Earnings Releases And Operating Results.

TORONTO, Aug. 26, 2024 (GLOBE NEWSWIRE) — Mitchell Cohen, Chief Executive Officer and President of Urbanfund Corp. (TSX-V: UFC) (“Urbanfund” or the “Company”), confirmed today that the Company has filed its financial statements for the three and six months ended June 30, 2024 (the “Consolidated Financial Statements”) and corresponding Management’s Discussion and Analysis (“MD&A”). BUSINESS OVERVIEW AND STRATEGY Business Overview Urbanfund Corp. is an incorporated entity listed on the TSX Venture Exchange (“TSX-V”) under the symbol UFC. The Company is a reporting issuer in Alberta, British Columbia and Ontario. Urbanfund’s focus is to invest in Canadian real estate and real estate related projects with a focus on a mix of both residential and commercial properties. The Company’s assets are located in Toronto, Brampton, Belleville,...

Lifecore Biomedical Reports Fourth Quarter and Fiscal Year End 2024 Financial Results and Provides Corporate Update

Written by Customer Service on August 26, 2024. Posted in Earnings Releases And Operating Results.

— Recorded Revenues of $128.3 million for Fiscal 2024; Year-Over-Year Increase of 24.2% —— High Value Pipeline Continues to Advance Toward Commercialization —— State-of-the-Art Technology Enhancements to Expand Capacityand New Business Opportunities – Conference Call Tomorrow Morning at 8:30 a.m. ET CHASKA, Minn., Aug. 26, 2024 (GLOBE NEWSWIRE) — Lifecore Biomedical, Inc. (NASDAQ: LFCR) (“Lifecore” or the “Company”), a fully integrated contract development and manufacturing organization (“CDMO”), today announced its financial results for the fourth quarter and full year of fiscal 2024. Highlights from Fiscal 2024: “Operationally, fiscal 2024 was a strong year for the Company as we recorded $128.3 million in revenues, representing a 24.2% increase over fiscal 2023,” stated Paul Josephs, president &...

Agile Therapeutics Inc. Announces Completion of Acquisition by Insud Pharma, S.L.

Written by Customer Service on August 26, 2024. Posted in Mergers And Acquisitions.

Agile Therapeutics has combined with Insud Pharma’s US Subsidiary, Exeltis USA, Inc., expanding an already significant women’s health/contraceptive portfolio Agile Therapeutics Common Shareholders to receive $1.52 per share of common stock Agile common stock will cease to be listed on the OTC QB PRINCETON, N.J., Aug. 26, 2024 (GLOBE NEWSWIRE) — Agile Therapeutics, Inc. (“Agile”) (OTCQB: AGRX), a women’s healthcare company, today announced the completion of the acquisition of Agile by Insud Pharma, S.L. (“Insud”) a global pharmaceutical group based in Spain with a 45-year track record and a presence in over 50 countries. The former holders of Agile common stock voted to approve the acquisition at a special meeting of stockholders on August 22, 2024. Upon closing of the acquisition, former shareholders of Agile became entitled...

BioSyent Declares Third Quarter 2024 Dividend

Written by Customer Service on August 26, 2024. Posted in Dividend Reports And Estimates.

MISSISSAUGA, Ontario, Aug. 26, 2024 (GLOBE NEWSWIRE) — BioSyent Inc. (“BioSyent”, “the Company”, TSX Venture: RX) is pleased to announce that its Board of Directors has declared a quarterly dividend of $0.045 per common share, payable in Canadian Dollars on September 15, 2024, to shareholders of record at the close of business on September 4, 2024. This third quarter 2024 dividend compares with the second quarter 2024 dividend of $0.045 per common share. This dividend qualifies as an ‘eligible dividend’ for Canadian income tax purposes. The declaration, timing, amount and payment of future dividends remain at the discretion of the Board of Directors. About BioSyent Inc. Listed on the TSX Venture Exchange under the trading symbol “RX”, BioSyent is a profitable growth-oriented specialty pharmaceutical company focused...

Teva to Present at the Morgan Stanley 22nd Annual Global Healthcare Conference

Written by Customer Service on August 26, 2024. Posted in Public Companies.

TEL AVIV, Israel, Aug. 26, 2024 (GLOBE NEWSWIRE) — Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that Richard Francis, Teva’s President and CEO, will present at the Morgan Stanley 22nd Annual Global Healthcare Conference on Wednesday, September 4, 2024. The presentation will begin at 11:30 A.M. Eastern Time. To access a live webcast of the presentation, visit Teva’s Investor Relations website at https://ir.tevapharm.com/Events-and-Presentations. An archived version of the webcast will be available within 24 hours after the end of the live discussion. About Teva Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) is a global pharmaceutical leader with a category-defying portfolio, harnessing our generics expertise and stepping up innovation to continue the momentum behind the discovery, delivery,...

Day: August 26, 2024

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Cookie Notice